全国免费电话:400-668-6834 -- 仅限中国地区 -- |
在线订购:QQ: 4006686834 电话订购:021-68591985 邮件订购:info@selleck.cn 我们也提供销售人员上门服务 |
技术支持电话:400-168-6834 我们将于一个工作日与您联系 |
![]() |
别名 | 储存条件 (自收到货起) |
3年 / -20°C / 粉状 1年 / -80°C / 溶于溶剂 |
|
化学式 | C28H22ClF3N6O3 |
|||
分子量 | 582.96 | CAS号 | 1448347-49-6 | |
Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (171.53 mM) | |
Ethanol | 100 mg/mL (171.53 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
产品描述 | Ivosidenib (AG-120) 是一种具有口服活性的IDH1(isocitrate dehydrogenase type 1)抑制剂,具有潜在的抗肿瘤活性。 | |
---|---|---|
靶点 |
|
|
体外研究 | 用AG-120处理TF-1细胞和携带突变IDH1的初级人类AML患者样品,降低了细胞内2-HG水平、抑制了不依赖于生长因子的细胞增殖以及恢复TF-1 IDH1-R132H细胞中由红细胞生成素所诱导的细胞分化。 同样地, 在初级人类母细胞中用AG-120抑制突变IDH1, 能有效降低2-HG水平以及诱导髓样分化[1]。 |
细胞实验 | 细胞系 | TF-1细胞 |
---|---|---|
浓度 | 0.5, 1.0, and 5.0 μM | |
处理时间 | 6 days | |
方法 | 用AG-120处理了TF-1细胞和携带突变IDH1的初级人类AML患者样品 |
数据来源于[Data independently produced by , , Oncol Rep, 2017, 38(6):3583-3591]
数据来源于[Data independently produced by , , ONCOLOGY REPORTS, 2017, 38: 3583-3591]
A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [ EBioMedicine, 2024, 102:105090] | PubMed: 38547578 |
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability [ Cancer Discov, 2023, 13(2):496-515] | PubMed: 36355448 |
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia [ Nat Commun, 2023, 14(1):5709] | PubMed: 37726279 |
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia [ Nat Commun, 2023, 14(1):5709] | PubMed: 37726279 |
Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation [ Cell Rep, 2023, 42(6):112578] | PubMed: 37267108 |
Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia [ Nat Commun, 2022, 13(1):2614] | PubMed: 35551192 |
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma [ NPJ Precis Oncol, 2022, 6-1:61] | PubMed: 36056177 |
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity [ Front Pharmacol, 2022, 13:871392] | PubMed: 35418865 |
The long non-coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics [ iScience, 2021, 24(11):103350] | PubMed: 34816103 |
Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil [ J Cancer, 2021, 12(16):4862-4872] | PubMed: 34234856 |
特定的存储和包装每个产品的信息在产品说明书上都有注明。大多数Selleck产品,在推荐的条件下存储可稳定保存两年。产品有时建议的储存温度不同,大多数建议储存在-20°C,抑制剂属于化学试剂,可在常温下运输储存两周左右。即使如此,我们保证产品的出货量将保持产品质量的条件下,一般都会放入冰袋。望阁下收到产品后,请按照产品数据表建议适当存储。
如果需要长期保存,请于零下二十度低温保存。禁止用于人体及治疗!
退换货政策
Selleck提供宽松的退换货承诺,努力为您营造最优的购物体验。每个订单Selleck只提供一次退换货服务,为了确保您的权益,请您仔细阅读以下内容:
1. 请在返还样品之前事先与我们取得联系,以确保产品是直接向我们或者当地代理商购买的;
2. 自收到货物起七天内,如因运输过程有问题或其他任何问题,您可以提出退换货要求;自收到货物起365天内,如因产品质量有问题,您可以提出退换货要求。
3. 请使用我们的快递账号进行退换货,您无需为此承担任何费用。
4. 如您已收到由Selleck开具的发票,则办理退货或订单金额发生变更的换货时,请将发票随商品一同返还给Selleck。请您妥善保管发票,如发票丢失,将无法办理退换货手续。
5. 对于合理的退换货要求,我们会在5个工作日内处理完成您的款项退还和新换货物的运输等,请耐心等待。